| Project/Area Number |
15K15499
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
村田 正治 九州大学, 先端融合医療レドックスナビ研究拠点, 准教授 (30304744)
赤星 朋比古 九州大学, 医学研究院, 准教授 (20336019)
橋爪 誠 九州大学, 医学研究院, 教授 (90198664)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肝硬変 / 星細胞 / 繊維化 / ナノキャリア / ナノバイオ / DDS / ナノバイオマテリアル / ナノ材料 |
|---|
| Outline of Final Research Achievements |
We aimed to develop an innovative drug nanocarriers targeting hepatic stellate cells using HSP 16.5 with no acute toxicity and no directivity to specific organs and tissues. HSP 16.5 immobilized via a hydrophilic polyethylene glycol linker was demonstrated to show nanoscale spherical structure specifically binds to hepatic stellate cells. The newly-developed drug nanocarrier in vivo in mice with liver cirrhosis showed high stable accumulation to the hepatic stellate cells with no toxicity. Histochemical evaluation of the liver showed that the drug nanocarrier accumulated in the whole liver especially in the sinusoidal area. This study may pave the way to develop the treatment for liver cirrhosis through the control of hepatic stellate cells.
|
